New Study Demonstrates GeneSight Psychotropic Better Predicts Blood Drug Levels When Compared to Single-Gene Testing
Myriad Genetics (NASDAQ: MYGN) announced a new study published in Psychiatry Research, showcasing the superiority of the GeneSight® Psychotropic test in predicting citalopram and escitalopram blood levels over single-gene tests. The study assessed 191 patients, demonstrating that GeneSight identifies more patients with significant gene-drug interactions, which might be missed by traditional methods.
- GeneSight test demonstrates a superior ability to predict blood drug levels compared to single-gene testing.
- The study involved a substantial sample size of 191 patients, enhancing research reliability.
- GeneSight identified more patients with significant gene-drug interactions, supporting clinical decision-making.
- The GeneSight test has been administered to over one million patients, indicating widespread clinical acceptance and use.
- None.
SALT LAKE CITY, June 08, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today a newly published study in Psychiatry Research. The study demonstrated the GeneSight® Psychotropic test is better at predicting citalopram and escitalopram blood concentrations when compared to single-gene testing.
The GeneSight test uses a combinatorial pharmacogenomic approach, which evaluates how variations in multiple genes may influence an individual’s outcomes with certain medications.
“The GeneSight test assesses and weighs multiple gene factors, which more accurately predicts blood drug levels and identifies more patients with significant gene-drug interactions who would be missed by single-gene testing,” said Michael R. Jablonski, Ph.D., vice president of medical affairs, Myriad Neuroscience. “The study provides further evidence to support the superiority of GeneSight’s combinatorial testing relative to single-gene methodologies and guideline recommendations.”
The new study assessed 191 patients from the GUIDED clinical study who were taking either citalopram (n=96) or escitalopram (n=95) at the time of their screening visit, had their dose specified, and provided a blood sample. Citalopram and escitalopram are routine first and second line treatments for major depressive disorder.
Current Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines make recommendations for citalopram based upon CYP2C19 metabolizer status. However, scientific evidence supports the role of additional genes (CYP2D6 and CYP3A4) in citalopram metabolism.
In the study, if testing was conducted on CYP2C19 alone, fewer patients with decreased metabolism for citalopram would have been identified. However, the combinatorial approach used by the GeneSight Psychotropic test identified more patients with decreased metabolism. Accordingly, more patients who could benefit from clinically actionable recommendations were identified. Furthermore, combinatorial pharmacogenomic testing explained more variance in citalopram blood levels when compared to single-gene testing.
About the GeneSight® Psychotropic Test
The GeneSight Psychotropic test is the category-leading pharmacogenomic test for depression medications. The test can help inform doctors about genes that may impact how patients metabolize or respond to certain depression medications. It has been given to more than one million patients by tens of thousands of physicians to provide genetic information that is unique to each patient. The GeneSight test supplements other information considered by a doctor as part of a comprehensive medical assessment. Learn more at GeneSight.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the Company’s strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Int’l, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.
| 20%; width: | 26%; width: (801) 505-5027 jmaxwell@myriad.com | 6%; width: | 22%; width: | 26%; width: (801) 584-1143 sgleason@myriad.com |
FAQ
What did Myriad Genetics announce on June 8, 2020?
What is the GeneSight Psychotropic test?
Why is the GeneSight test considered superior to single-gene testing?
How many patients were involved in the study published in Psychiatry Research?
What are citalopram and escitalopram used for?
